Sartorius Stedim Biotech stock analysis
Sartorius Stedim Biotech (56S1) Stock Price & Analysis
56S1 Stock Chart & Stats
- Day’s Range
- EUR 221.60 - EUR 228.20
- 52-Week Range
- EUR 151.50 - EUR 229.00
- Previous Close
- EUR 227.00
- Volume
- N/A
- Average Volume (3M)
- 52
- Market Cap
- EUR 22.07B
- Enterprise Value
- EUR 22.86B
- Total Cash (Recent Filing)
- EUR 172.00M
- Total Debt (Recent Filing)
- EUR 2.31B
- Price to Earnings (P/E)
- 66.7
- Beta
- 1.10
- Next Earnings
- Feb 23, 2027 (Est.)
- EPS Estimate
- 1.47
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.31%
Bulls Say, Bears Say
Bulls Say
Recurring Consumables And Installed Base
The mix of frequently replaced consumables and installed equipment creates repeat purchasing beyond one-time capital sales. As biopharmaceutical customers expand production, this model can support durable customer relationships, recurring revenue, and greater visibility across future manufacturing cycles.
Healthy Operating Margins
Gross and EBITDA margins remain healthy for the business, indicating meaningful value creation from its bioprocessing technologies, equipment, and consumables. These margins provide operating capacity to support research, product development, customer service, and growth investment over the next several quarters.
Improved Financial Stability
The substantial reduction in debt-to-equity strengthens the balance sheet relative to 2023 and improves financial flexibility. Higher equity and lower relative leverage should make it easier to fund operations and strategic investment while reducing the balance-sheet strain associated with prior debt levels.
Bears Say
Weak Cash Conversion
Positive operating and free cash flow are not converting efficiently from reported earnings, which reduces the quality and flexibility of profit generation. If this pattern persists, the company may have less internally generated cash available for investment, debt reduction, or shareholder returns.
Volatile Earnings Recovery
The recovery demonstrates improvement, but the multi-year earnings profile remains volatile and is still described as being in a rebuild phase. Performance below the 2022 peak means future results remain sensitive to the pace of biopharmaceutical production growth and customer capacity expansion.
Meaningful Debt And Moderate Returns
Although leverage has improved, the remaining debt burden is still material relative to the company’s current return profile. Moderate ROE suggests capital is not yet generating returns comparable with prior highs, limiting the strength of balance-sheet efficiency and leaving less room for execution setbacks.
Sartorius Stedim Biotech News
56S1 FAQ
What was Sartorius Stedim Biotech’s price range in the past 12 months?
What is Sartorius Stedim Biotech’s market cap?
When is Sartorius Stedim Biotech’s upcoming earnings report date?
How were Sartorius Stedim Biotech’s earnings last quarter?
Is Sartorius Stedim Biotech overvalued?
Does Sartorius Stedim Biotech pay dividends?
What is Sartorius Stedim Biotech’s EPS estimate?
How many shares outstanding does Sartorius Stedim Biotech have?
What happened to Sartorius Stedim Biotech’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sartorius Stedim Biotech?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Sartorius Stedim Biotech
Sartorius Stedim Biotech S.A., a global entity and a subsidiary of Sartorius AG, delivers critical instruments, consumables, and services tailored for the biopharmaceutical industry. Their extensive product portfolio includes fundamental components like cell lines, cell culture media, and bioreactors, alongside comprehensive solutions for separation, purification, and concentration processes. They also provide specialized systems for the safe storage and transport of biological intermediates and finished products. For advanced applications, particularly in cell and gene therapy, the company offers both single-use and reusable hollow-fiber membrane devices and presterilized assemblies. Beyond physical products, their service offerings cover vital bioprocessing steps such as cell cultivation, fermentation, filtration, purification, and fluid management, in addition to cell harvesting and broader solutions for intensified bioprocesses. Furthermore, Sartorius Stedim Biotech provides advanced data analytics software designed to model and optimize biopharmaceutical development and production workflows. Serving a diverse customer base, including pharmaceutical, food, and chemical manufacturers, as well as research and development laboratories, the company was founded in 1870 and operates from its headquarters in Aubagne, France.
- Sector
- General
- Industry
- Medical - Instruments & Supplies
- CEO
- Rene Faber
- Employees
- 10,483
- Website
- www.sartorius.com
- Address
- Zone Industrielle Les Paluds, Aubagne, PAC, 13781, FR
Sartorius Stedim Biotech (56S1) Earnings & Revenues
56S1 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 6 | 4 |
| Technical Analysis | 4 | 6 | 0 |
| Moving Averages | 8 | 0 | 4 |
